Steriwave ICU Pilot Study

Launched by FRASER HEALTH · Mar 6, 2025

Keywords

ClinConnect Summary

The Steriwave ICU Pilot Study is a research project aimed at helping patients in the critical care unit at Royal Columbian Hospital. This study is looking at a method called antimicrobial photodynamic therapy (aPDT), which uses light to help reduce harmful bacteria in the nose. The goal is to see if using this method can prevent serious infections, such as pneumonia and bloodstream infections, which can occur in patients on ventilators or those staying in the hospital for a longer time.

To join this study, participants need to be at least 19 years old and expected to stay in the ICU for more than two days. Unfortunately, pregnant or breastfeeding individuals, those with certain allergies, or those who can't tolerate the treatment won't be able to participate. If someone decides to join, they will be monitored to see how well this therapy works and how it affects the bacteria in their noses. This study will help researchers understand if a larger study is possible in the future and provide important information about preventing infections in ICU patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All ICU patients 19 years and above
• • Expected length of ICU stay \>48 hrs
• Exclusion Criteria:
• • Pregnant/breastfeeding individuals
• • Allergy to methylene blue and/or chlorhexidine gluconate, or unknown allergy status
• • Nasal or facial trauma that limits access to the nose
• • Inability for the patients to tolerate or comply with treatment, as determined by their treating physician
• • Patient, TSDM or MRP declines participation
• • Co-enrolment with other research studies will be considered in an individual basis.